Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Bottom Line?

Bottom Line?

posted on Jun 10, 2008 07:57AM

It would appear then, if there is no restrictive language in the license agreement, the assumption is that the patent owner has obtained the full value of the license and patent exhaustion occurs with the first sale. And if that is the case, then there is no real impact on us, assuming that TPL has been using restrictive language in its license agreements. Well, that's the way I see it. But my eyes are not so good. IMHO Opty

Share
New Message
Please login to post a reply